Gout risk in adults with pre-diabetes initiating metformin
Main finding · Incident goutResult — go to the resultHazard ratio 0.68 95% CI 0.48–0.96Authors' conclusion
Metformin use was associated with a reduced risk of gout among adults with pre-diabetes
Study context
- Population
- Adults with pre-diabetes (defined by haemoglobin A1c), academic health system EHR, 2007–202225,064 with pre-diabetes identified
- Participants
- 1,154 vs 13,877
- Exposure
- Metformin initiators vs non-users of antidiabetic medications
- Metforminn = 1,154
- Non-usersn = 13,877reference
- Outcome
- Incident gout
Methodological detailsnew-user, propensity score-matched, electronic health records, single academic health system
- New-user
- Propensity score-matched
- Electronic health records
- Single academic health system
Main finding
As reported in the abstract
median follow-up 3.9 years
Hazard ratio
0.68
95% CI 0.48–0.96
By group
Metforminvs Non-users
HR 0.68 (95% CI 0.48–0.96)
Observational data: associations, not effects.
Further findings
Changes in serum urate or C-reactive protein (CRP)
- No relationship between metformin and changes in serum urate (SU) or CRP
Original publication
Gout risk in adults with pre-diabetes initiating metformin. Ann Rheum Dis. Published 30 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →